Oxford Asset Management’s Reviva Pharmaceuticals Warrants RVPHW Stock Holding History

Oxford Asset Management’s Portfolio RVPHW Stock Details RVPHW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-216,100	Closed	-$32K	–	1090
2019 Q4	$32K	Sell	216,100 -1,000	-0.5%	-$229	﹤0.01%	1684
2019 Q3	$54K	Sell	217,100 -500	-0.2%	-$96	﹤0.01%	1651
2019 Q2	$46K	Sell	217,600 -52,400	-19%	-$10.5K	﹤0.01%	1638
2019 Q1	$43K	Hold	270,000	–	–	﹤0.01%	1604
2018 Q4	$89K	Buy	+270,000	New	+$86.6K	﹤0.01%	1664

Other funds holding RVPHW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

BCM

Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return

Oxford Asset Management's RVPHW Position: Q1 2020 in Review

Oxford Asset Management sold out of Reviva Pharmaceuticals Warrants (RVPHW) in Q1 2020, closing a stake of 216,100 shares — an estimated $32K sold.

Oxford Asset Management first reported a position in RVPHW in Q4 2018 and held it in 5 quarters. The position peaked at $89K in Q4 2018. 17 funds tracked by Wall St. Rank hold RVPHW as of Q1 2020.

Oxford Asset Management reported no remaining Reviva Pharmaceuticals Warrants position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 216,100 Reviva Pharmaceuticals Warrants shares in Q1 2020, an estimated $32K.
Oxford Asset Management first reported a position in Reviva Pharmaceuticals Warrants in Q4 2018 and held it in 5 quarters.
Oxford Asset Management's Reviva Pharmaceuticals Warrants position peaked at $89K in Q4 2018.
17 funds tracked by Wall St. Rank held Reviva Pharmaceuticals Warrants as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.